|Day Low/High||31.75 / 33.00|
|52 Wk Low/High||27.88 / 44.56|
When the central bank is on top of their game as they have been of late, credit must go where credit is due.
The daily trading volume has increased over the past two months telling us that PFE is not falling of its own weight but rather investors are voting with their feet.
But don't throw up your arms yet -- here are names that could be golden opportunities.
Here's how we would play shares of the pharmaceutical giant now.
These Dow stocks all yield above 3.3% right now, but are they worth the risk?
This coronavirus remains a China-centric problem? People are not yet dying in other countries. Do we have to worry here? That's the wrong question.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
Also: People's Bank of China, the Fed, U.S./China trade deal, Brexit, USMCA.
The planned acquisition of The Medicines Company by Novartis spurs prospects of other deals in the drug business.
These stocks are priced for total imperfection. That's just what you want.
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
What new management means for Mylan shareholders moving forward.
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.